Reproducibility of LPS-Induced ex vivo Cytokine Response of Healthy Volunteers Using a Whole Blood Assay.

LPS endotoxin inflammation lipopolysaccharide

Journal

Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684

Informations de publication

Date de publication:
2024
Historique:
received: 28 02 2024
accepted: 19 06 2024
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 25 7 2024
Statut: epublish

Résumé

Lipopolysaccharide (LPS) stimulation of human whole blood ex vivo has been widely used to investigate human innate immune responses. However, there are uncertainties regarding the reproducibility and reliability of this assay. In this prospective, single-center study, cytokine responses (interleukin 8, interferon-α, interferon-γ, interleukin 10, interleukin 1-β, interleukin 6, and tumor necrosis factor-α) to ex vivo whole blood LPS stimulation were assessed in 12 healthy volunteers. Cytokine levels were measured at 0, 2, and 4 h using a multiplex immunoassay (Luminex The lowest mean coefficients of variation were observed for the technical replicates (5.4 to 9.2%), followed by the biological replicates (8.1 to 24.8%), and the repeated experiments after 6 weeks (17 to 31.2%). Between the baseline and 6-week AUCs, the following Pearson correlation coefficients R were observed: interleukin 10, 0.97; interferon-α, 0.84; interleukin 1-β, 0.83; interleukin 8, 0.79; interleukin 6, 0.73; interferon-γ, 0.73; and tumor necrosis factor-α, 0.63. The level of agreement between the baseline and week-6 cytokine response to ex vivo LPS stimulation was high across the seven cytokines analyzed. While interleukin 10 exhibited the lowest level of variability over time, tumor necrosis factor-α showed the highest variability in repeated experiments, which should be considered in the design and interpretation of future studies.

Identifiants

pubmed: 39051050
doi: 10.2147/JIR.S459999
pii: 459999
pmc: PMC11268716
doi:

Types de publication

Journal Article

Langues

eng

Pagination

4781-4790

Informations de copyright

© 2024 Jorda et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Lancet Microbe. 2023 Sep;4(9):e692-e703
pubmed: 37659419
Methods Mol Biol. 2017;1546:169-176
pubmed: 27896766
J Immunol. 2021 Jul 15;207(2):696-708
pubmed: 34261668
Cell. 2016 Nov 3;167(4):1111-1124.e13
pubmed: 27814508
Intensive Care Med. 2011 Mar;37(3):525-32
pubmed: 21153402
Nutr Clin Pract. 2008 Feb;23(1):76-84
pubmed: 18203967
J Immunol Methods. 2018 Sep;460:119-124
pubmed: 30056942
Crit Care Med. 2008 Jan;36(1):159-65
pubmed: 18007272
Antimicrob Agents Chemother. 1992 Oct;36(10):2139-46
pubmed: 1444293
Shock. 2016 May;45(5):490-4
pubmed: 27089173
Eur Cytokine Netw. 2017 Mar 1;28(1):19-26
pubmed: 28840841
J Antimicrob Chemother. 2007 Feb;59(2):219-23
pubmed: 17114176
Inflamm Res. 2022 Mar;71(3):331-341
pubmed: 35157090
Shock. 2006 Feb;25(2):129-34
pubmed: 16525350
J Immunol Methods. 1998 Sep 1;218(1-2):63-71
pubmed: 9819123
Toxicol Ind Health. 2002 Feb;18(1):15-27
pubmed: 12703679
J Mol Med (Berl). 2023 Feb;101(1-2):183-195
pubmed: 36790534
Innate Immun. 2010 Aug;16(4):248-53
pubmed: 19710091
Innate Immun. 2017 Jul;23(5):432-439
pubmed: 28443392
J Clin Invest. 2023 Jan 17;133(2):
pubmed: 36282571

Auteurs

Anselm Jorda (A)

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria.

Sabine Eberl (S)

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria.

Alina Nussbaumer-Pröll (A)

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria.

Maysa Sarhan (M)

Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis, Vienna, Austria.

Maria Weber (M)

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria.

Lara Elisabeth Tegrovsky (LE)

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria.

Markus Wahrmann (M)

Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis, Vienna, Austria.

Valentin Al Jalali (V)

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria.

Felix Bergmann (F)

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria.
Medical University of Vienna, Department of Plastic, Reconstructive and Aesthetic Surgery, Vienna, Austria.

Lena Pracher (L)

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria.

Amelie Leutzendorff (A)

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria.

Matthias Farlik (M)

Medical University of Vienna, Department of Dermatology, Vienna, Austria.

Bernd Jilma (B)

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria.

Markus Zeitlinger (M)

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria.

Classifications MeSH